Abbott Laboratories
Every calculator, already run for ABT
Open the full toolkit →You have the numbers on ABT. Get the argument.
A written report on which of these readings actually decide the outcome for Abbott Laboratories, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
27 analysts covering ABTAnalyst Price Target Disagreement for Abbott Laboratories
Wall Street's bull case implies +32% from the current price; the bear case implies +0%. A 31% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ABT
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromy…
ABT — frequently asked
Is ABT a buy right now?
Wall Street's consensus rating on Abbott Laboratories is Buy across 27 analysts, with a mean price target of $120.26 (+17% vs. the current $102.61). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ABT overvalued?
ABT trades at 33.2x trailing earnings, against a DCF fair value of $133 per share. The current price implies 3% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ABT's next earnings date?
Abbott Laboratories is next scheduled to report earnings around Oct 14, 2026. A full ABT research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Abbott Laboratories?
Analysts covering Abbott Laboratories (ABT) range from a bear-case target of $103.00 to a bull-case high of $135.00, with a mean consensus target of $120.26 across 25 analysts. The spread of $32.00 (31% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Abbott Laboratories against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Abbott Laboratories
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ABT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Abbott Laboratories, in minutes. 3 free reports included with every account — no credit card required.